Published
February 7, 2022
Key Messages
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses zanubrutinib (Brukinsa), 80 mg oral capsules.
- Indication: Treatment of adult patients with Waldenström macroglobulinemia (lymphoplasmacytic lymphoma).
